FDMT 4dmoleculartherapeutics.com Intermediate Coverage Ratio

4D Molecular Therapeutics (FDMT) creates universal vectors for the therapy of various pathologies, generating revenue through technology licensing without capital expenditures. Historical price action reflects a current value of 7.69, while the absence of sales and the clinical status of the project lead to a proportional increase in research costs. Leading specialists, motivated by stock options and scientific autonomy, drive the business development.

The ratio is calculated as the sum of cash and accounts receivable divided by current liabilities. This metric assesses a business's ability to immediately settle its debts without liquidating inventory. For 4D Molecular Therapeutics (FDMT) and its high-tech AAV platforms, such liquidity is critical when funding costly clinical trials. The acid-test liquidity trend clearly demonstrates the financial stability of management during the drug development period.